ACME Laboratories (DHA:ACMELAB) Piotroski F-Score: N/A (As of Jun. 28, 2026)


DHA:ACMELAB ACME Laboratories Ltd DHA:ACMELAB
82 GF Score
Price BDT81.30
GF Value BDT124.74
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is ACME Laboratories Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

ACME Laboratories has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for ACME Laboratories's Piotroski F-Score or its related term are showing as below:

During the past 9 years, the highest Piotroski F-Score of ACME Laboratories was 9. The lowest was 2. And the median was 6.

ACME Laboratories  (DHA:ACMELAB) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


ACME Laboratories Piotroski F-Score Related Terms


ACME Laboratories Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for ACME Laboratories's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACME Laboratories Piotroski F-Score Chart

ACME Laboratories Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only 5.00 7.00 7.00 6.00 6.00

ACME Laboratories Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 5.00 7.00 7.00 N/A

DHA:ACMELAB vs ZTS, UTHR, VTRS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ACME Laboratories Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where ACME Laboratories's Piotroski F-Score falls into.


DHA:ACMELAB
82GF Score
ACME Laboratories Ltd DHA:ACMELAB
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Dec24) TTM:
Net Income was 594.997 + 636.25 + 655.907 + 697.892 = BDT2,585 Mil.
Cash Flow from Operations was 193.28 + 1495.332 + 1077.463 + 1613.38 = BDT4,379 Mil.
Revenue was 9251.673 + 9885.463 + 10137.805 + 10439.683 = BDT39,715 Mil.
Gross Profit was 3948.988 + 4103.382 + 4255.277 + 4266.572 = BDT16,574 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Mar26) was
(58095.635 + 58564.095 + 59009.044 + 60115.544 + 59535.015) / 5 = BDT59063.8666 Mil.
Total Assets at the begining of this year (Dec24) was BDT58,096 Mil.
Long-Term Debt & Capital Lease Obligation was BDT7,100 Mil.
Total Current Assets was BDT26,222 Mil.
Total Current Liabilities was BDT21,887 Mil.
Net Income was 582.295 + 650.428 + 552.821 + 605.003 = BDT2,391 Mil.

Revenue was 8004.48 + 8391.837 + 8340.544 + 8762.301 = BDT33,499 Mil.
Gross Profit was 3409.527 + 3490.365 + 3455.934 + 3721.278 = BDT14,077 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was
(0 + 54275.899 + 55622.164 + 55779.015 + 58095.635) / 5 = BDT55943.17825 Mil.
Total Assets at the begining of last year (Dec23) was BDT0 Mil.
Long-Term Debt & Capital Lease Obligation was BDT6,707 Mil.
Total Current Assets was BDT25,630 Mil.
Total Current Liabilities was BDT23,611 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

ACME Laboratories's current Net Income (TTM) was 2,585. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

ACME Laboratories's current Cash Flow from Operations (TTM) was 4,379. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=2585.046/58095.635
=0.04449639

ROA (Last Year)=Net Income/Total Assets (Dec23)
=2390.547/0
=

ACME Laboratories's return on assets of this year was 0.04449639. ACME Laboratories's return on assets of last year was . ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

ACME Laboratories's current Net Income (TTM) was 2,585. ACME Laboratories's current Cash Flow from Operations (TTM) was 4,379. ==> 4,379 > 2,585 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Mar26
=7099.997/59063.8666
=0.12020881

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=6706.839/55943.17825
=0.11988663

ACME Laboratories's gearing of this year was 0.12020881. ACME Laboratories's gearing of last year was 0.11988663. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=26221.882/21886.899
=1.19806291

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=25630.498/23610.881
=1.08553755

ACME Laboratories's current ratio of this year was 1.19806291. ACME Laboratories's current ratio of last year was 1.08553755. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

ACME Laboratories's number of shares in issue this year was 211.482. ACME Laboratories's number of shares in issue last year was 211.539. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=16574.219/39714.624
=0.41733289

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=14077.104/33499.162
=0.42022257

ACME Laboratories's gross margin of this year was 0.41733289. ACME Laboratories's gross margin of last year was 0.42022257. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=39714.624/58095.635
=0.68360771

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=33499.162/0
=

ACME Laboratories's asset turnover of this year was 0.68360771. ACME Laboratories's asset turnover of last year was . ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+0+1+1+0+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

ACME Laboratories has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?

Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued. The current stock price of BDT81.30 is trading 34.8% below its estimated GF Value™ of BDT124.74. GuruFocus considers ACME Laboratories to be Possible Value Trap.

Key valuation signals for DHA:ACMELAB:

  • Piotroski F-Score: N/A
  • GF Value™: BDT124.74 vs. price of BDT81.30 (34.8% below fair value)
  • GF Score™: 82/100 with 7 warning signs

No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ACME Laboratories Business Description

Address 1/4, Kallayanpur, Mirpur Road, Court de la ACME, Dhaka, BGD, 1207
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
82GF Score

Get the complete analysis for DHA:ACMELAB

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT81.30
Price
BDT124.74
GF Value